AC
AVTX icon

Armistice Capital’s Avalo Therapeutics AVTX Stock Holding History

Armistice Capital’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-18,396
Closed -$7.73M – 227
2023
Q1 		$7.73M Buy
18,396
+1,877
+11% +$1.48M 0.11% 99
2022
Q4 		$20M Hold
16,519
– – 0.35% 53
2022
Q3 		$13.2M Hold
16,519
– – 0.23% 67
2022
Q2 		$23.8K Hold
16,519
– – 0.42% 56
2022
Q1 		$34.5M Buy
16,519
+894
+6% +$2.25M 0.67% 45
2021
Q4 		$76.5M Hold
15,625
– – 1.25% 16
2021
Q3 		$98.1M Buy
15,625
+2,049
+15% +$16.6M 1.66% 11
2021
Q2 		$128M Buy
13,576
+2,245
+20% +$18.8M 2.29% 3
2021
Q1 		$98.6M Buy
11,331
+868
+8% +$8.2M 2.26% 3
2020
Q4 		$79.6M Buy
10,463
+41
+0.4% +$285K 2.71% 3
2020
Q3 		$68.3M Buy
10,422
+35
+0.3% +$263K 2.48% 3
2020
Q2 		$77.8M Buy
10,387
+609
+6% +$4.42M 3.41% 3
2020
Q1 		$69.8M Buy
9,778
+2,596
+36% +$27.5M 4.32% 3
2019
Q4 		$111M Hold
7,182
– – 6.43% 3
2019
Q3 		$68M Buy
7,182
+783
+12% +$8.74M 4.51% 3
2019
Q2 		$100M Buy
6,399
+43
+0.7% +$652K 6.32% 2
2019
Q1 		$107M Buy
6,356
+61
+1% +$913K 5.85% 2
2018
Q4 		$58.6M Buy
6,295
+218
+4% +$2.43M 4.44% 3
2018
Q3 		$81.7M Buy
6,077
+378
+7% +$4.95M 4.91% 2
2018
Q2 		$71.2M Buy
5,699
+126
+2% +$1.5M 4.65% 2
2018
Q1 		$68.9M Hold
5,573
– – 5.27% 2
2017
Q4 		$51.4M Buy
5,573
+17
+0.3% +$73.2K 5.12% 2
2017
Q3 		$13.6M Buy
5,556
+4,381
+373% +$9.38M 1.6% 21
2017
Q2 		$1.94M Buy
+1,175
New +$1.92M 0.25% 54

Other funds holding AVTX

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Armistice Capital's AVTX Position: Q2 2023 in Review

Armistice Capital sold out of Avalo Therapeutics (AVTX) in Q2 2023, closing a stake of 18,396 shares — an estimated $7.73M sold.

Armistice Capital first reported a position in AVTX in Q2 2017 and held it in 24 quarters. The position peaked at $128M in Q2 2021. 22 funds tracked by Wall St. Rank hold AVTX as of Q2 2023.

  • Armistice Capital reported no remaining Avalo Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Armistice Capital sold 18,396 Avalo Therapeutics shares in Q2 2023, an estimated $7.73M.
  • Armistice Capital first reported a position in Avalo Therapeutics in Q2 2017 and held it in 24 quarters.
  • Armistice Capital's Avalo Therapeutics position peaked at $128M in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2023.

Based on Armistice Capital's 13F filing for Q2 2023, filed 14 Aug 2023.